title: MBX-500 is effective for treatment of Clostridium difficile infection in gnotobiotic piglets.
abstract: The novel antibiotic MBX-500, dosed at 100, 200, or 400 mg/kg twice daily for 7 days, was evaluated for the treatment of Clostridium difficile infection (CDI) in the gnotobiotic pig model. MBX-500 increased survival at all doses and at high doses improved clinical signs and reduced lesion severity, similar to vancomycin. Our results show that MBX-500 is an effective antibiotic for the treatment of diarrhea associated with CDI and prevents severe systemic disease.
authors.affiliation: Tufts Cummings School of Veterinary Medicine, Department of Infectious Disease and Global Health, North Grafton, Massachusetts, USA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Steele
authors.forename: Quanshun
authors.initials: Q
authors.lastname: Zhang
authors.forename: Gillian
authors.initials: G
authors.lastname: Beamer
authors.forename: Michelle
authors.initials: M
authors.lastname: Butler
authors.forename: Terry
authors.initials: T
authors.lastname: Bowlin
authors.forename: Saul
authors.initials: S
authors.lastname: Tzipori
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016360:Clostridioides difficile / Q000472:pathogenicity*; D003015:Clostridium Infections / Q000188:drug therapy*; D003106:Colon / Q000382:microbiology / Q000473:pathology; D003967:Diarrhea / Q000188:drug therapy* / Q000382:microbiology; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D024841:Fluoroquinolones / Q000494:pharmacology*; D005856:Germ-Free Life; D053208:Kaplan-Meier Estimate; D011744:Pyrimidinones / Q000494:pharmacology*; D012720:Severity of Illness Index; D013552:Swine; D016896:Treatment Outcome; D014640:Vancomycin / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; C585474:MBX-500; D011744:Pyrimidinones; D014640:Vancomycin